MX2009010210A - Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-d iaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas. - Google Patents

Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-d iaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas.

Info

Publication number
MX2009010210A
MX2009010210A MX2009010210A MX2009010210A MX2009010210A MX 2009010210 A MX2009010210 A MX 2009010210A MX 2009010210 A MX2009010210 A MX 2009010210A MX 2009010210 A MX2009010210 A MX 2009010210A MX 2009010210 A MX2009010210 A MX 2009010210A
Authority
MX
Mexico
Prior art keywords
phenyl
decan
trifluoromethyl
ethoxy
bis
Prior art date
Application number
MX2009010210A
Other languages
English (en)
Spanish (es)
Inventor
Wing-Kee Philip Cho
Zhihui Qiu
Na Zhao
Victor Ming-She Wong
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39541515&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009010210(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009010210A publication Critical patent/MX2009010210A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2009010210A 2007-03-22 2008-03-20 Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-d iaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas. MX2009010210A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91950107P 2007-03-22 2007-03-22
PCT/US2008/003653 WO2008118331A2 (fr) 2007-03-22 2008-03-20 Formulations pour comprimés contenant des sels de 8-[{1-(3,5-bis- (trifluorométhyl)phényl)-éthoxy}-méthyl]-8-phényl-1,7-diaza-spiro[4,5]- décan-2-one et comprimés

Publications (1)

Publication Number Publication Date
MX2009010210A true MX2009010210A (es) 2009-10-19

Family

ID=39541515

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010210A MX2009010210A (es) 2007-03-22 2008-03-20 Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-d iaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas.

Country Status (11)

Country Link
US (3) US8361500B2 (fr)
EP (1) EP2136793B1 (fr)
JP (3) JP5442459B2 (fr)
AR (1) AR065802A1 (fr)
CA (1) CA2681465C (fr)
CL (1) CL2008000819A1 (fr)
ES (1) ES2406934T3 (fr)
MX (1) MX2009010210A (fr)
PE (1) PE20081891A1 (fr)
TW (1) TWI350185B (fr)
WO (1) WO2008118331A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030762A1 (es) 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
JP5155998B2 (ja) 2006-04-05 2013-03-06 オプコ ヘルス， インコーポレイテッド 薬学的処方物：８−［｛１−（３，５−ビス−（トリフルオロメチル）フェニル）−エトキシ｝−メチル］−８−フェニル−１，７−ジアザ−スピロ［４．５］デカン−２−オンの塩およびそれを使用した処置方法
CA2648604C (fr) * 2006-04-05 2016-05-24 Schering Corporation Sels hydrochloridriques de 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one et procede de preparation associe
WO2008000042A1 (fr) 2006-06-30 2008-01-03 Iceutica Pty Ltd Procédés de préparation de composés biologiquement actifs sous forme de nanoparticules
AR065802A1 (es) * 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
AR066191A1 (es) * 2007-03-22 2009-08-05 Schering Corp Proceso e intermediarios para la sintesis de compuestos 8- [ ( 1- (3,5- bis- ( trifluorometil) fenil) - etoxi ) - metil]- 8 fenil - 1,7- diaza - espiro (4, 5) decan -2 ona
TW200942531A (en) 2008-03-17 2009-10-16 Bial Portela & Companhia S A Crystal forms of a nitrocatechol
AU2009289598B2 (en) 2008-09-05 2014-09-11 Opko Health, Inc. Process and intermediates for the synthesis of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl) -ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
DK2413913T3 (da) * 2009-04-01 2022-06-13 Bial Portela & Ca Sa Farmaceutiske formuleringer omfattende nitrocatecholderivater og fremgangsmåder til fremstilling deraf
DK2413912T3 (da) 2009-04-01 2019-06-17 Bial Portela & Ca Sa Farmaceutiske formuleringer, der omfatter nitrocatecholderivater, og metoder til fremstilling deraf
NZ595902A (en) * 2009-04-24 2014-10-31 Iceutica Pty Ltd Method for the production of commercial nanoparticle and microparticle powders
WO2010121324A1 (fr) * 2009-04-24 2010-10-28 Iceutica Pty Ltd Nouvelle formulation de métaxalone
NZ595986A (en) 2009-04-24 2014-04-30 Iceutica Pty Ltd A novel formulation of indomethacin
AP3138A (en) * 2009-04-24 2015-02-28 Iceutica Pty Ltd Production of encapsulated nanoparticles at high volume fractions
EA201171281A1 (ru) * 2009-04-24 2012-05-30 Айсьютика Пти Лтд. Производство инкапсулированных наночастиц в коммерческих масшатабах
PH12015501811A1 (en) * 2009-04-24 2019-03-25 Iceutica Pty Ltd Production of encapsulated nanoparticles at high volume fractions
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
WO2011019911A1 (fr) * 2009-08-14 2011-02-17 Opko Health, Inc. Formulations intraveineuses d'antagonistes de neurokinine-1
GB2475701B (en) * 2009-11-26 2011-10-19 Michael Hilary Burke A process for the preparation of an orally administered anthelmintic unit dose tablet
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
US9452107B2 (en) 2012-04-16 2016-09-27 New Jersey Institute Of Technology Systems and methods for superdisintegrant-based composite particles for dispersion and dissolution of agents
EP2976086B1 (fr) 2013-03-22 2020-10-14 Millennium Pharmaceuticals, Inc. Combinaison d'inhibiteurs catalytiques de mtorc1/2 et inhibiteurs sélectifs de la kinase aurora a
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
CN106866669A (zh) * 2017-04-19 2017-06-20 成都百特万合医药科技有限公司 一种合成罗拉吡坦中间体的方法
KR20210152506A (ko) * 2019-07-19 2021-12-15 더 글로벌 얼라이언스 포 티비 드러그 디벨롭먼트, 잉크. 프레토마니드 조성물
WO2023080910A1 (fr) * 2020-11-18 2023-05-11 Fb-Hrs, Llc Compositions contenant du dofétilide et de la mexilétine et leurs utilisations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100405116B1 (ko) 1995-02-28 2004-02-05 아벤티스 파마슈티칼스 인크. 피페리디노알칸올화합물에대한약제학적조성물
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US6499984B1 (en) 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
AU2001286237A1 (en) * 2000-09-22 2002-04-02 Sumitomo Pharmaceuticals Company, Limited Oral preparations with favorable disintegration characteristics
PE20030762A1 (es) * 2001-12-18 2003-09-05 Schering Corp Compuestos heterociclicos como antagonistas nk1
US20040077677A1 (en) * 2002-09-17 2004-04-22 Wyeth Oral formulations
RS20060198A (en) 2003-10-03 2008-09-29 Pfizer Limited, Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activ ity for the treatment of hiv and inflammation
WO2005063243A1 (fr) 2003-12-22 2005-07-14 Schering Corporation Compositions pharmaceutiques
WO2005097076A2 (fr) * 2004-04-09 2005-10-20 Smithkline Beecham Corporation Produits pharmaceutiques a faibles doses
US7354922B2 (en) * 2004-12-14 2008-04-08 Schering Corporation Bridged ring NK1 antagonists
CA2648604C (fr) * 2006-04-05 2016-05-24 Schering Corporation Sels hydrochloridriques de 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one et procede de preparation associe
JP5155998B2 (ja) * 2006-04-05 2013-03-06 オプコ ヘルス， インコーポレイテッド 薬学的処方物：８−［｛１−（３，５−ビス−（トリフルオロメチル）フェニル）−エトキシ｝−メチル］−８−フェニル−１，７−ジアザ−スピロ［４．５］デカン−２−オンの塩およびそれを使用した処置方法
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas

Also Published As

Publication number Publication date
JP2013216694A (ja) 2013-10-24
TW200902087A (en) 2009-01-16
US20150283121A1 (en) 2015-10-08
EP2136793A2 (fr) 2009-12-30
EP2136793B1 (fr) 2013-02-20
JP5442459B2 (ja) 2014-03-12
JP5763134B2 (ja) 2015-08-12
CA2681465C (fr) 2015-12-15
US20100104637A1 (en) 2010-04-29
AR065802A1 (es) 2009-07-01
CA2681465A1 (fr) 2008-10-02
TWI350185B (en) 2011-10-11
WO2008118331A2 (fr) 2008-10-02
CL2008000819A1 (es) 2008-09-26
ES2406934T3 (es) 2013-06-10
US8361500B2 (en) 2013-01-29
US20130122088A1 (en) 2013-05-16
JP2010522173A (ja) 2010-07-01
JP2015108023A (ja) 2015-06-11
JP6041919B2 (ja) 2016-12-14
WO2008118331A3 (fr) 2009-04-23
PE20081891A1 (es) 2008-12-27

Similar Documents

Publication Publication Date Title
MX2009010210A (es) Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-d iaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas.
SG170838A1 (en) Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}- methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor
MY149731A (en) Compounds
WO2007114921A3 (fr) Formulations pharmaceutiques : sels de 8-[{1-(3,5-bis (trifluoromethy1)pheny1)-e thoxy}-methy1]-8-pheny1-1,7-diaza-spiro[4.5] decan-2-one et méthodes de traitement utilisant lesdits sels
MX2012004420A (es) Compuestos de espiropiperidino y uso farmaceutico de los mismos para tratar diabetes.
MX2010002419A (es) (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
GB0722077D0 (en) Compounds
MX2010002461A (es) (carboxilalquilenfenil)feniloxamidas, metodo para su produccion y uso de las mismas como medicamento.
EA201490477A1 (ru) Фармацевтические составы, содержащие пропиленгликоль-гидрат дапаглифлозина
MX2013005445A (es) Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2).
MX2012006233A (es) Nuevos compuestos de espiropiperidina.
TNSN08513A1 (en) Carbonylated (aza) cyclohexanes as dopamine d3 receptor ligands
GEP20125589B (en) TRIAZINE COMPOUNDS AS P13 KINASE AND mTOR INHIBITORS
UY32156A (es) Derivados sustituidos de la n2 - [1-(5 - fluoropirimidin -2-il) etil] - n4 - (1-metil - 1h-imidazol - 4 - il)) - pirimidina - 2,4 - diaminas y sus sales farmacéuticamente aceptables, proceso de preparación, composiciones conteniéndolos y aplicaciones.
MX2011011335A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
WO2011092469A8 (fr) 1-(5-tert-butyl-2-phényl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-méthyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phényl]-urée et composés associés, et leur utilisation dans des traitements
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
HK1136828A1 (en) Spirocyclic cyclohexane derivatives
EA201491658A1 (ru) Таблетки для комбинированной терапии
MX2013012588A (es) Inhibidores de cinasa.
WO2009013545A3 (fr) Composés chimiques
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.
NZ616300A (en) Novel rock inhibitors
MX355734B (es) Formas cristalinas de clorhidrato de 1- (3-ter-butil-1-p-tolil-1h- pirazol-5-il)-3- (5-fluoro-2- (1- (2- hidroxietil) -indazol-5-iloxi) bencil) urea..
MX2012006287A (es) Activadores de azaindol glucocinasa.

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration